CUV clinuvel pharmaceuticals limited

Ann: Preliminary results from SCENESSE adolescent EPP study, page-3

  1. 18,369 Posts.
    lightbulb Created with Sketch. 5231
    When you put everything together you can really see how spectacular and long lasting the growth associated with the self-funded dilution-free expansion will likely be - with high (explosive) growth likely lasting well into the 2030s. From about this financial year and onwards (and especially 2026) we have multiple new major revenue sources coming online. Record expansion in distribution centres this financial year, indication expansion in existing EPP market, indication expansion into a completely new and substantially larger market (vitiligo), expansion into highly disruptive cosmetics with huge addressable markets (DNA Repair and Sunless Tanning / natural sun protection).

    All this and we get full exposure to the upside due to zero dilution required to unlock these opportunities, and that upside starts from a ridiculously low valuation multiple (so that means we get to see both a major multiple expansion, and share price growth associated the general growth of the company)
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$9.83
Change
-0.350(3.44%)
Mkt cap ! $492.7M
Open High Low Value Volume
$10.18 $10.18 $9.75 $1.391M 140.2K

Buyers (Bids)

No. Vol. Price($)
1 9965 $9.83
 

Sellers (Offers)

Price($) Vol. No.
$9.89 370 1
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.